Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology develops experimental cancer drugs, led by an antibody drug conjugate for head and neck squamous cell carcinoma. It last closed at $1.44 on Nov 17, up 2.13% on the day. The average 12-month price target from 4 analysts is $10.25 (+611.8% from the last close), with a high of $19.00 and a low of $7.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From PYXS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on PYXS in the past 90 days. The average target is $10.25, with a high of $19.00 and a low of $7.00, compared with the last close of $1.44.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 6 | RBC Capital | Maintained | Buy | $7 |
| Nov 6 | Wedbush | Target lowered | Buy | $8 → $7 |
| Sep 10 | Wedbush | Target raised | Buy | $6 → $8 |
| Sep 10 | HC Wainwright & Co. | Target raised | Buy | $7 → $8 |
| Sep 9 | Wells Fargo | Target raised | Buy | $12 → $19 |
Technical Analysis
The stock is 17% below its 20 day and 55% below its 50 day average. It is 50% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 31), near oversold. The nearest support is the Pivot S1 at $1.35, and the nearest resistance the Pivot R1 at $1.53.
| RSI (14) | 31.12 | Weak, oversold below 30 | Neutral |
| MACD | -0.18 | Above its signal line | Bullish |
| Stochastic | 9.8 | Near the bottom of its range | Oversold |
| ADX (14) | 37.0 | Trending down | |
| Williams %R | -85.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -170.7 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −12.2% | Change over 10 sessions | Bearish |
| ATR (14) | $0.15 | Typical daily range, 10.2% of price |
| RSI (14) | 38.92 | Weak, oversold below 30 | Neutral |
| MACD | -0.21 | Below its signal line | Bearish |
| Stochastic | 4.0 | Near the bottom of its range | Oversold |
| ADX (14) | 19.3 | No clear trend | |
| Williams %R | -96.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -120.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −55.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.55 | Typical daily range, 38.5% of price |
What happened before
See how PYXS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PYXS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in PYXS in the last 90 days.
PYXS Institutional Ownership
Full report →- ▲64 buying vs 32 selling
- ▲Held by funds +38.2 pts
- ▲Funds holding +25
- ▲Superinvestors: 3 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 101 | 76 | +32.9% |
| In funds' top 10 | 4 | 2 | +100.0% |
| Held by funds | 66.7% | 28.6% | +38.2 pts |
| New / increased | 38 / 26 | 9 / 24 | +93.9% |
| Reduced / sold out | 19 / 13 | 24 / 10 | −5.9% |
| Put/call ratio | 0.00 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PYXS is in one of them and how their past PYXS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PYXS in an article yet. Here's the latest on the wider market.
About Pyxis Oncology
Pyxis Oncology is a cancer drug developer based in Boston, Massachusetts. Its lead product candidate, micvotabart pelidotin, is an experimental antibody drug conjugate that targets a protein found in the tissue surrounding tumors rather than on cancer cells themselves. The company is focused on head and neck squamous cell carcinoma and is testing the drug alone and together with Keytruda, an immunotherapy made by Merck. The drug is still in clinical testing and is not approved for sale, and it is aimed at patients with solid tumors.
- Headquarters
- Boston, MA




